Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

When we launched the drug, we expected to be at 75% by the end of six months,” Gilead CFO Andrew Dickinson told B ...

Patrick and Charles Boyd bought more than $90 million of the illicit drugs and sold them to unwitting customers in South ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...

We often encounter patients taking multiple medications, which complicates choosing safe and effective antimicrobial ...

Researchers used cryo-EM to study how the HIV enzyme integrase arranges in 3D to slip its DNA into the host genome and pack ...

"You know, it's not the best news. But there was other news that could have been a lot worse, you know?" Charlie Sheen said.

A pioneering opt-out testing programme for HIV, hepatitis B, and hepatitis C in NHS emergency departments has identified thousan ...